Pear Therapeutics SPAC: Everything you need to know about Pear
Oliver Brett July 20, 2021 7:40 AM
Pear Therapeutics is the first company of its type to gain federal approval in the US for apps that treat psychiatric ailments. It has investors intrigued as it plots a SPAC as a route to going public.
What is Pear Therapeutics?
Pear Therapeutics is a biotechnology and software company. It offers prescription digital therapeutics that that seek to manage or treat psychiatric and neurological diseases.It is headquartered in Boston, Massachusetts and was founded in 2013 by Corey McCann, Stephen Smith and William Greene. Significantly, it has rolled out multiple products that have received landmark approval from the United States' Food and Drug Administration (FDA).
Launched in 2013, it immediately targeted mental health and in doing so responded to a clear gap in the market, according to McCann, who has an MD and PhD in neurobiology.
How do Pear Therapeutics' apps work?
The flagship product of Pear Therapeutics is reSET, a 90-day prescription app that provides cognitive behavioural therapy for the treatment of substance use disorder and is intended to be used as a complimentary or parallel treatment to regular outpatient consultation. The list price for a 90-day prescription is $1,665.In 2017, ReSET was the first mobile app to receive FDA authorization to treat alcohol, cocaine, marijuana and stimulant use disorders. ReSET-O, which is indicated for the treatment of opioid use disorder, received FDA authorization in 2018, followed by Somryst, Pear’s app to treat chronic insomnia in 2020.
Why does reSET cost $1,665 for 90 days?The $1,665 price tag for a single course of ReSET prescription treatment can be mitigated by setting it alongside the health costs associated with patients who do not use the app, according to McCann
He cites studies that demonstrate the app lowered overall healthcare spending for patients by reducing emergency room visits and hospitalisation to the tune of around $2,150 per patient.
McCann says: "We built the company with this insight that software could be a new category within healthcare. Software can specifically treat diseases in many of the same ways that you currently think about drugs."
What is Pear Therapeutics' IPO plan?Pear Therapeutics plans to go public in a $1.6 billion special purpose acquisition corporation, or SPAC deal. Pear has already raised more than $250 million to date with Softbank leading the start-up’s Series D funding round.
- Read More: What is a SPAC and how do they work?
- Analysis: Our full guide to the latest IPOs and SPACs
Pear is essentially betting on mainstream acceptance of prescription digital therapeutics - either on their own or in conjunction with pharmaceutical drugs and traditional psychiatric consultation.
To that end, the company's projections that around 150,000 prescriptions will be written in 2023, amounting to around $125 million in revenue and a 3,025% increase in a two-year period, may seem if not fanciful then certainly on the optimistic side.
How can Pear achieve exponential growth?That’s where the SPAC deal comes in. Pear is merging with Thimble Point Acquisition Corp, a blank check company associated with Hyatt Hotel billionaire heiress Karen Pritzker.
Following the completion of a reverse merger planned for the second half of 2021, Pear will have access to gross proceeds of around $400 million. Most will be in the form of cash, but $125 million will come in the form of private investment in the stock, much of it from Pear’s existing investors, such as Softbank, Novartis and Jazz Venture Partners.
It can be safely assumed that Pear will use a large percentage of these funds to considerably step up its marketing efforts. Its agreement with the Sandoz division of Novartis to co-market its apps came to an end in 2019 and a re-think is required.
What is Pear's marketing strategy?Charting the way forward, McCann told Forbes: “It's a space that really requires commercial companies to operate and iterate at the speed that you would probably normally associate with tech. It became fairly clear that this was really a space that needed a bespoke commercialization engine.
“Because of Covid, we have this really interesting, perfect storm within addiction and behavioral health conditions, where there are more triggers and less access for patients. At the heart of our commercial deployments is really in trying to bring access to patients where they are.”
Pear has contracts with 15 payors - typically Medicaid organisations - each with one million members or more. This gives Pear strong market depth in Kentucky, Indiana and Ohio.
Who is on Pear Therapeutics' executive team?
- Corey McCann, President & CEO
- Chris Guiffre, CFO & COO
- Erin Brenner, Chief Product Development Officer
- Kathy Jeffery, Chief People Officer
- Yuri Maricich, Chief Medical Officer & Head of Development
- Ronan O'Brien, General Counsel & Secretary
- Julia Strandberg, Chief Commerical Officer
What else does Pear have in its pipeline?Pear is developing a range of new products. It is actively acquiring existing assets from third-party providers which it then refines before distribution. It also has its own staff creating other new products from scratch.
For example, Pear bought apps for post-traumatic stress disorder from USC, acute and chronic pain from Firsthand Technology, and irritable bowel syndrome from the Karolinska Institute in Sweden.
Meanwhile, it is developing its own apps for schizophrenia, depression and epilepsy, among other diseases.
The SPAC deal “allows us to have the fully-funded plan to really make Pear the leader in this space,” McCann says. “The deepest and broadest pipeline, but also all of those assets rolling up to the same platform and to really become the de facto platform for the space.”
How to trade stocks at FOREX.com
You can trade stocks with FOREX.com from some jurisdictions using spread-bets or CFDs, with spreads from 0.1%. Follow these easy steps to start trading now.
Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.
Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.